Podcasts about royalties

Bryan Kohberger can't leave his cell — but his story can. In the state of Idaho, there's no Son of Sam law, meaning that a convicted murderer can legally make money from the story of his crimes. Books. Documentaries. Interviews. Royalties. In this episode, Tony Brueski and former prosecutor Eric Faddis expose how one of the most horrifying modern murder cases has collided with one of America's oldest constitutional blind spots: the First Amendment's protection of speech — even when that speech turns into profit from murder. Tony opens with the question every viewer needs to hear: How can a convicted killer make money from killing? The answer lies in a 1991 Supreme Court ruling, Simon & Schuster v. Crime Victims Board, which struck down New York's original Son of Sam law after the “Son of Sam” killer, David Berkowitz, tried to sell his story. The Court ruled that laws restricting “crime-based storytelling” discriminated against speech by content. States rewrote their laws to pass constitutional review — some succeeded, others failed — but Idaho never passed anything. The result: a legal vacuum where infamy becomes an industry. This episode breaks down the moral, legal, and economic consequences of that loophole. What does it mean for victims' families when killers can cash checks? Could Kohberger assign rights to a third party to hide profits? And why are lawmakers too afraid to fix it? Tony and Eric dissect how “freedom” became a shield for greed, how fear of being called unconstitutional paralyzed reform, and why the justice system now doubles as a business model. Justice shouldn't have a payout plan. This episode asks why America keeps writing one. #BryanKohberger #SonOfSam #TrueCrime #JusticeSystem #CrimePodcast #VictimsRights #TonyBrueski #EricFaddis #KohbergerTrial #FreeSpeech #MurderProfit #TrueCrimeAnalysis Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/@hiddenkillerspod Instagram https://www.instagram.com/hiddenkillerspod/ Facebook https://www.facebook.com/hiddenkillerspod/ Tik-Tok https://www.tiktok.com/@hiddenkillerspod X Twitter https://x.com/tonybpod Listen Ad-Free On Apple Podcasts Here: https://podcasts.apple.com/us/podcast/true-crime-today-premium-plus-ad-free-advance-episode/id1705422872

Bryan Kohberger can't leave his cell — but his story can. In the state of Idaho, there's no Son of Sam law, meaning that a convicted murderer can legally make money from the story of his crimes. Books. Documentaries. Interviews. Royalties. In this episode, Tony Brueski and former prosecutor Eric Faddis expose how one of the most horrifying modern murder cases has collided with one of America's oldest constitutional blind spots: the First Amendment's protection of speech — even when that speech turns into profit from murder. Tony opens with the question every viewer needs to hear: How can a convicted killer make money from killing? The answer lies in a 1991 Supreme Court ruling, Simon & Schuster v. Crime Victims Board, which struck down New York's original Son of Sam law after the “Son of Sam” killer, David Berkowitz, tried to sell his story. The Court ruled that laws restricting “crime-based storytelling” discriminated against speech by content. States rewrote their laws to pass constitutional review — some succeeded, others failed — but Idaho never passed anything. The result: a legal vacuum where infamy becomes an industry. This episode breaks down the moral, legal, and economic consequences of that loophole. What does it mean for victims' families when killers can cash checks? Could Kohberger assign rights to a third party to hide profits? And why are lawmakers too afraid to fix it? Tony and Eric dissect how “freedom” became a shield for greed, how fear of being called unconstitutional paralyzed reform, and why the justice system now doubles as a business model. Justice shouldn't have a payout plan. This episode asks why America keeps writing one. #BryanKohberger #SonOfSam #TrueCrime #JusticeSystem #CrimePodcast #VictimsRights #TonyBrueski #EricFaddis #KohbergerTrial #FreeSpeech #MurderProfit #TrueCrimeAnalysis Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/@hiddenkillerspod Instagram https://www.instagram.com/hiddenkillerspod/ Facebook https://www.facebook.com/hiddenkillerspod/ Tik-Tok https://www.tiktok.com/@hiddenkillerspod X Twitter https://x.com/tonybpod Listen Ad-Free On Apple Podcasts Here: https://podcasts.apple.com/us/podcast/true-crime-today-premium-plus-ad-free-advance-episode/id1705422872

Bryan Kohberger can't leave his cell — but his story can. In the state of Idaho, there's no Son of Sam law, meaning that a convicted murderer can legally make money from the story of his crimes. Books. Documentaries. Interviews. Royalties. In this episode, Tony Brueski and former prosecutor Eric Faddis expose how one of the most horrifying modern murder cases has collided with one of America's oldest constitutional blind spots: the First Amendment's protection of speech — even when that speech turns into profit from murder. Tony opens with the question every viewer needs to hear: How can a convicted killer make money from killing? The answer lies in a 1991 Supreme Court ruling, Simon & Schuster v. Crime Victims Board, which struck down New York's original Son of Sam law after the “Son of Sam” killer, David Berkowitz, tried to sell his story. The Court ruled that laws restricting “crime-based storytelling” discriminated against speech by content. States rewrote their laws to pass constitutional review — some succeeded, others failed — but Idaho never passed anything. The result: a legal vacuum where infamy becomes an industry. This episode breaks down the moral, legal, and economic consequences of that loophole. What does it mean for victims' families when killers can cash checks? Could Kohberger assign rights to a third party to hide profits? And why are lawmakers too afraid to fix it? Tony and Eric dissect how “freedom” became a shield for greed, how fear of being called unconstitutional paralyzed reform, and why the justice system now doubles as a business model. Justice shouldn't have a payout plan. This episode asks why America keeps writing one. #BryanKohberger #SonOfSam #TrueCrime #JusticeSystem #CrimePodcast #VictimsRights #TonyBrueski #EricFaddis #KohbergerTrial #FreeSpeech #MurderProfit #TrueCrimeAnalysis Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/@hiddenkillerspod Instagram https://www.instagram.com/hiddenkillerspod/ Facebook https://www.facebook.com/hiddenkillerspod/ Tik-Tok https://www.tiktok.com/@hiddenkillerspod X Twitter https://x.com/tonybpod Listen Ad-Free On Apple Podcasts Here: https://podcasts.apple.com/us/podcast/true-crime-today-premium-plus-ad-free-advance-episode/id1705422872

Bryan Kohberger can't leave his cell — but his story can. In the state of Idaho, there's no Son of Sam law, meaning that a convicted murderer can legally make money from the story of his crimes. Books. Documentaries. Interviews. Royalties. In this episode, Tony Brueski and former prosecutor Eric Faddis expose how one of the most horrifying modern murder cases has collided with one of America's oldest constitutional blind spots: the First Amendment's protection of speech — even when that speech turns into profit from murder. Tony opens with the question every viewer needs to hear: How can a convicted killer make money from killing? The answer lies in a 1991 Supreme Court ruling, Simon & Schuster v. Crime Victims Board, which struck down New York's original Son of Sam law after the “Son of Sam” killer, David Berkowitz, tried to sell his story. The Court ruled that laws restricting “crime-based storytelling” discriminated against speech by content. States rewrote their laws to pass constitutional review — some succeeded, others failed — but Idaho never passed anything. The result: a legal vacuum where infamy becomes an industry. This episode breaks down the moral, legal, and economic consequences of that loophole. What does it mean for victims' families when killers can cash checks? Could Kohberger assign rights to a third party to hide profits? And why are lawmakers too afraid to fix it? Tony and Eric dissect how “freedom” became a shield for greed, how fear of being called unconstitutional paralyzed reform, and why the justice system now doubles as a business model. Justice shouldn't have a payout plan. This episode asks why America keeps writing one. #BryanKohberger #SonOfSam #TrueCrime #JusticeSystem #CrimePodcast #VictimsRights #TonyBrueski #EricFaddis #KohbergerTrial #FreeSpeech #MurderProfit #TrueCrimeAnalysis Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/@hiddenkillerspod Instagram https://www.instagram.com/hiddenkillerspod/ Facebook https://www.facebook.com/hiddenkillerspod/ Tik-Tok https://www.tiktok.com/@hiddenkillerspod X Twitter https://x.com/tonybpod Listen Ad-Free On Apple Podcasts Here: https://podcasts.apple.com/us/podcast/true-crime-today-premium-plus-ad-free-advance-episode/id1705422872

No podcast ‘Notícia No Seu Tempo’, confira em áudio as principais notícias da edição impressa do jornal ‘O Estado de S.Paulo’ desta sexta-feira (31/10/2025): Projetos relacionados à segurança pública estacionados há meses no Congresso estão sendo retomados e uma CPI do Crime Organizado será instalada. A PEC da Segurança Pública volta a ser discutida pelos parlamentares. Governadores de oposição, reunidos no Rio, anunciaram a criação de um “Consórcio da Paz” para que Estados se ajudem no enfrentamento à criminalidade. O presidente Luiz Inácio Lula da Silva sancionou a lei que endurece o combate ao crime e amplia a proteção de autoridades envolvidas nessa área. Governo e oposição tentam calibrar a narrativa na semana em que operação policial contra o Comando Vermelho, no Rio, deixou 121 mortos. O episódio acentuou a polarização política no País e antecipa um tema que deve ser central na campanha de 2026. E mais: Economia: Congresso aprova MP que muda regras do setor elétrico Metrópole: Desmatamento cai 11% na Amazônia e no Cerrado Internacional: Rússia e China rebatem ameaça de Trump de retomar testes nucleares Cultura: Filme sobre Springsteen traz a juventude e os dramas do ídoloSee omnystudio.com/listener for privacy information.

NESTA EDIÇÃO. As discussões em torno das mudanças no preço de referência para cálculo de royalties incluídas na MP do setor elétrico. No segundo dia da OTC Brasil 2025, diretora de E&P da Petrobras, Sylvia Anjos, diz que companhia reduziu incertezas sobre Sergipe Águas Profundas e que pode antecipar primeiro óleo. MME começar a estudar viabilidade de aumento das misturas para 25% de biodiesel no diesel e 35% de etanol na gasolina.

No podcast ‘Notícia No Seu Tempo’, confira em áudio as principais notícias da edição impressa do jornal ‘O Estado de S.Paulo’ desta quinta-feira (30/10/2025): O Complexo da Penha, na zona norte do Rio, amanheceu com mais de 60 cadáveres expostos na rua. Os corpos foram recolhidos numa mata por moradores e enfileirados horas após operação policial que deixou pelo menos 121 mortos – quatro deles policiais. A Defensoria fala em 132 mortes. De acordo com o secretário estadual da PM, Marcelo de Menezes, agentes do Bope (Batalhão de Operações Policiais Especiais) se posicionaram na área mais alta da Serra da Misericórdia, que divide os complexos da Penha e do Alemão, formando um “muro” que empurrou os criminosos para o topo da montanha. “A opção pelo confronto se deu pelos marginais, pelos narcoterroristas. Aqueles que quiseram ser presos foram presos.”Alguns dos corpos estavam amarrados e com marcas de facadas. O Estadão viu um corpo decapitado. O governo do Rio diz que a estratégia foi necessária para avançar sobre um território dominado pelo Comando Vermelho (CV) e considerou a operação um “sucesso”. E mais: Economia: Mexida em royalties afeta Petrobras e ajuda refinaria no AM, terra do relator Política: Revisão criminal na 2ª Turma pode dar a Bolsonaro a chance de anular sentença Metrópole: Câmara aprova reajuste do IPTU com limite anual de 10% para todo imóvel Internacional: Ataques israelenses em Gaza matam 104, segundo autoridades palestinas Esportes: João Fonseca sucumbe diante de russo e se despede de ParisSee omnystudio.com/listener for privacy information.

NESTA EDIÇÃO. Relatório da MP da reforma do setor elétrico ganha mecanismos que impactam mercado de óleo e gás, incluindo alteração na base de cálculo de royalties e mecanismo para expansão de gasodutos. Os destaques do primeiro dia da OTC Brasil 2025, com a Margem Equatorial no centro dos debates. Governo recorre ao STJ contra a liberação de atividades da Refinaria de Manguinhos. Brasil negocia prioridade na compra de semicondutores chineses em meio à crise geopolítica.

Brendan Yurik joins the KE Report to discuss Electric Royalties (TSX.V:ELEC - OTC:ELECF) expanding portfolio and path to sustainable cash flow. The company now holds 43 royalties focused on key electrification metals across top-tier jurisdictions. Discussion Highlights First Cash-Flowing Asset: Copper-gold royalty at the Punitaqui Copper Mine (Chile) ramping up - expected to cover annual G&A. Next in Line: Four royalties could begin paying within 12 months. Advancing Projects: Feasibility and PFS updates coming from multiple assets. Diversified Exposure: Balanced across copper, lithium, graphite, manganese, nickel, zinc, tin, and vanadium; no single asset >15% of NAV. Growth Outlook: Targeting one or two near-term, revenue-generating royalties backed by private equity to boost cash flow with minimal dilution. Click here to visit the Electric Royalties website to learn more about the Company   -------------- For more market commentary & interview summaries, subscribe to our Substacks: The KE Report: https://kereport.substack.com/ Shad's resource market commentary: https://excelsiorprosperity.substack.com/ Investment disclaimer: This content is for informational and educational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any security. Investing in equities and commodities involves risk, including the possible loss of principal. Do your own research and consult a licensed financial advisor before making any investment decisions. Guests and hosts may own shares in companies mentioned.

Sister Nancy Tells Her Story: No Royalties, 9–5 Job, The Return Of A Legend With 'Armageddon' +MoreSee omnystudio.com/listener for privacy information.

IP Group PLC CEO Greg Smith talked with Proactive's Stephen Gunnion about the group's potential future royalties following Pfizer's acquisition of obesity drug developer Metsera. The transaction valued the business at up to $7.3bn, including $4.9bn in upfront cash. Metsera has a portfolio of promising therapeutic candidates and combinations with four programmes in clinical development and several next-generation programmes with IND-enabling studies ongoing, aimed at addressing key unmet needs via fewer injections while achieving improved efficacy and tolerability. Smith explained that IP Group is the licensor of the fundamental technology behind Metsera's lead compounds. If those drugs are approved and reach the market, Smith said the company could benefit from “some quite substantial royalties.” He added that Metsera aims to begin phase three trials by the end of 2025, with analysts forecasting first sales by 2029 or 2030. Smith said the underlying technology originated from the work of Professor Stephen Bloom at Imperial College in London. Smith also addressed how this royalty stream could shape IP Group's long-term strategy, suggesting that ongoing revenue might support its permanent capital model. Turning to recent developments, Smith said IP Group realised around £160 million in cash from exits in 2024, including sales to Visa, Everfox and CoreWeave. He noted confidence in hitting over £250 million in realisations from the private portfolio by 2027. Smith also discussed the company's £4 million investment into OXCCU as part of a $28 million funding round, citing strong third-party interest in sustainable aviation fuel technologies. Visit Proactive's YouTube channel for more interviews like this one — and don't forget to like, subscribe, and turn on notifications for future content. #IPGroup #GregSmith #PfizerDeal #BiotechInvestment #ObesityDrugs #Metsera #OXCCU #SustainableAviationFuel #VentureCapital #PharmaRoyalties #DeepTech #LifeSciences #PrivateEquity #InvestorNews #ProactiveInvestors

Making a Scene Presents - AI in Metadata & File Prep: Smarter Exports for DistributionWhat is metadata, and why should you care about it?Imagine this: you write a song, record it, and then send it out into the world. But who “owns” that song? Who wrote it? Who should get paid when people listen? How will streaming services or radio stations know which song it is, among millions of others? That's where metadata comes in.Metadata is “data about data.” In music, metadata is all the information attached to a recording (or a track) that describes it: the song title, who the artist is, who wrote it, who owns it, when it was released, the track number on an album, and unique codes like an ISRC (International Standard Recording Code). Without good metadata, your track is like a book without a cover or title page—it's hard to identify, harder to track, and easier to lose. http://www.makingascene.org

In questa diretta capirai se le 7 fonti di reddito sono una grande idea oppure un epic fail!Guarda la replica del webinar “L'immobiliare intelligente" per scoprire opportunità e rischi dell'investimento immobiliare. 

CPAs translate fame into cash flow, contracts, and accountability. Accounting ARC - Student-Led ConversationsWith Harshita MultaniCenter for Accounting TransformationIn a special episode of Accounting ARC: Student-Led Conversations, student host Harshita Multani interviews Jeff Frable, CPA, CGMA, a partner at CCK Strategies in Tulsa, Okla.; Aurmaudra Bradley, CPA, president of the NABA Indianapolis Chapter; and video producer Dave Maresca with the Center for Accounting Transformation and CPA Trendlines, about the financial mechanics behind modern entertainment—and the accountants who make the numbers work.  MORE Accounting ARC: Free Speech Is a Right; Respect Is a Responsibility | Cash Bags, Casinos & Audits: How First Jobs Shape Us | Gen Z Redefines Careers | Bootleggers, Baptitsts & CPAs: Rethinking Licensure | CPA Firm Ownership Under Fire | Walking Violation: When Showing Your CPA Gets You in Trouble | Audit Bags to TikTok Tags, Gen Z Talks Success | Students Challenge Accounting's Traditional Career Path | True Grit: Recognizing Struggles That Shape Our Successes |More Admins, Fewer Students, No Plan | What Career Advice Gets Wrong for Gen Z - And How to Fix It | Your Identity is Not a Liability | Burnout, Be Gone: Accounting Needs a Boundary Breakthrough The panel opens with favorites ranging from the movie “Back to the Future” to the TV show “Lost,” then quickly moves to the business beneath the screen. Bradley says the shift from box office and album sales to streaming platforms fundamentally changes how talent gets paid and how accountants track performance. She points to the recent labor actions in Hollywood as an example of residual models catching up to platform economics. In 2023, both the Writers Guild of America and SAG-AFTRA cited the rise of streaming and reduced residuals as central issues during historic strikes that disrupted production across the industry.  Frable emphasizes that the profession's core value does not change. “You do you, and I'll do me,” he says. Artists and athletes deserve to focus on their craft while accountants manage contracts, taxes, and cash flow.

I've been a full-time creator for 8 years now and have earned $2,192,000 since 2022. I've spent a LOT of time and money experimenting with different ways to make money on the internet, so I'm going to rank them. The best and the worst. I show you 15 different revenue streams and rate them from S to F based on their potential versus the effort required. By the very end of the video, you'll know which ones are right for you. And at any point, if you agree or disagree, let me know in the comments. ⁠⁠⁠⁠⁠⁠⁠Full transcript and show notes⁠⁠⁠⁠⁠⁠⁠ *** TIMESTAMPS (00:32) AdSense (01:36) Sponsorship & Brand Deals (03:30) Content Memberships (04:30) Done-For-You Services (05:27) Royalties (06:28) 1-to-1 Coaching & Consulting (07:38) Affiliates (09:36) User Generated Content (UGC) (10:17) Group Programs (11:25) Digital Products (12:56) Speaking (14:27) Live Events (15:53) Community Memberships *** RECOMMENDED NEXT EPISODE → ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠#267: When to use low-ticket offers, refund policies, how much I earned in the last 12 months, and my 5-year vision [Ask CS Pt. 1] *** ASK CREATOR SCIENCE → ⁠⁠⁠⁠⁠⁠⁠Submit your question here⁠⁠⁠⁠⁠⁠⁠ *** WHEN YOU'RE READY

I sit down with Conni Francini, CEO of Soro Publishing, to explore how she's building a more author-friendly path to publishing. Conni traces her unconventional route—from journalism/PR into education, then a 15-year run in educational publishing where she rose to editor-in-chief and developed award-winning products with partners like the Smithsonian and TIME for Kids.After dozens of candid chats with writers—frustrated by low royalties, limited marketing, slow timelines, and losing creative control—Conni launched Soro Publishing. The model blends the best of traditional and self-publishing: professional editorial and design, months-not-years timelines, authors keeping their rights, creative control, and most royalties, plus a true partnership to grow their platforms.We dig into Soro's three focus lanes—education, business/leadership, and children's books—and what's surprised Conni most about entrepreneurship: the sheer build-from-scratch workload, the importance of loving sales/BD as much as “making the book,” and staying adaptable when the market pulls you into new genres. Conni also shares hard-won lessons for leading creatives (define outcomes, not pixel-perfect solutions) and encouragement for first-time founders and execs: ask for help early and often—you'll be surprised how many people say yes.What You Will LearnWhy many authors feel stuck between traditional and self-publishing—and how a hybrid model can be a win-win.The specific ways Soro helps authors retain rights, voice, and royalties while leveling up quality and speed.How to lead multidisciplinary creative teams: set audience outcomes, invite expertise, and critique by problem, not by prescription.The underestimated realities of starting a company (and how to balance making the product with marketing/business development).How to stay adaptable when real-world feedback nudges your strategy into new lanes.Practical networking advice for new execs/founders: how (and why) to ask for guidance from leaders you don't even know yet.Resources MentionedConni Francini on LinkedInSoro PublishingInstagram — @soropublishingPast partnerships referenced: Smithsonian, TIME for Kids

This episode is a discussion on how AI is impacting the music industry, hosted by Stu Watts and features guests Joe Carra (Grammy nominated mastering engineer) and Simon Moro (producer/engineer/mixer).Joe Carra is the chief mastering engineer and owner of Crystal Mastering. With over 3 decades of experience, Joe has mastered for cassette, vinyl, CD, and in recent times, embraced the immersive audio of Dolby Atmos. In 2020 Joe received a Grammy nomination for Best Engineered Album, for the Teskey Brothers ‘Run Home Slow' album. Joe has mastered various ARIA award winning albums and in 2023, was recognised with a nomination in the MPEG Awards for 'Mastering Engineer of the Year'. Joe's credits include Pond, The Slingers, King Gizzard & The Lizard Wizard, Courtney Barnett, Amyl & The Sniffers, Genesis Owusu, The Murlocs, San Cisco, Babe Rainbow, Bliss N Eso, The Waifs and many more.Simon Moro is a music producer, sound engineer, mixer and co-owner of The Avenue Recording Studio and has over 25 years of experience. His unique ability to empathetically connect with an artist and understand their vision was born out of training under Michael Brauer (Coldplay, The Kooks, Grizzly Bear) which taught him that capturing the essence of the artist is paramount to creating the best mix. Having worked with labels such as Sony and Mushroom, artists such as Anthony Callea and Allday, mixed and produced ARIA nominated albums, live albums, and television shows, he knows that no project is too bold and ambitious, and no detail is too minute to matter.Chapters:00:00 Intro02:25 Joe's Client's AI-Generated Album07:10 The Evolution of AI Music Generation12:59 AI's Role in Music Production20:43 Why Human Mastering Still Thrives Against AI33:35 The Risk of Homogenised Music vs. Authentic Human Art40:53 The Fight for Fair Credits and Royalties in AI Music49:04 Using AI Tools Without Losing Creative Human Skills01:01:15 Final Thoughts: AI, Copyright, and the Value of Human EffortHow you can support the podcast:⁠⁠⁠⁠⁠⁠⁠Subscribe on YouTube⁠⁠⁠⁠⁠⁠Buy some merch⁠⁠⁠⁠⁠⁠Donate⁠⁠⁠Follow on Instagram:⁠⁠⁠⁠⁠⁠⁠What's That Sound?⁠⁠⁠⁠⁠⁠Stu Watts⁠⁠⁠Joe CarraSimon Moro⁠⁠⁠Stu Watts website⁠Crystal Mastering websiteSimon Moro website⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Listen to Stu's work on Spotify⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Listen to Joe's work on Spotify⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Enquiries and suggestions: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠podcast.whatsthatsound@gmail.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ 

Chaque année, près d'un tiers des droits musicaux disparaissent sans jamais parvenir à leurs créateurs. Ce sont environ 15 milliards d'euros de redevances qui se perdent dans la complexité des métadonnées, les erreurs de correspondance et la fragmentation des systèmes nationaux de gestion collective. C'est ce déséquilibre que la jeune pousse française Claimy s'emploie à corriger, en combinant intelligence artificielle et expertise du secteur musical.Become a supporter of this podcast: https://www.spreaker.com/podcast/frenchweb-business--3299227/support.

In this JCO Article Insights episode, Dr. Ece Cal interviews Dr. Martin Wermke, author of the JCO article, "Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas." TRANSCRIPT The disclosures for guests on this podcast can be found in the transcript. Dr. Ece Cali: Welcome to this episode of JCO Article Insights. This is Dr. Ece Cali, JCO editorial fellow, and today I am joined by Dr. Martin Wermke, Professor for Experimental Cancer Therapy at Dresden University of Technology, to discuss the manuscript “Phase 1 Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-like T-Cell Engager Obrixtamig in Patients with DLL3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas.” Obrixtamig is a bispecific T-cell engager that binds to DLL3 on tumor cells and CD3 on T-cells. This manuscript presents the phase 1A dose escalation results of Obrixtamig in patients with DLL3+ small cell lung cancer and neuroendocrine carcinomas. In this study, 168 patients were treated with Obrixtamig across four different dosing regimens. 49% of the patients had small cell lung cancer, 42% had extrapulmonary neuroendocrine carcinoma, and 8% had large cell neuroendocrine carcinoma of the lung. Patients received a median of two prior lines of therapy. 33% of the patients had brain metastases at baseline. Of note, this trial did not mandate baseline brain imaging. Maximum tolerated dose was not reached. 88% of the patients experienced a treatment-related adverse event, however, only 3.6% of the patients had to discontinue treatment due to treatment-related AEs, and dose reduction due to treatment-related AEs was documented in 2.4% of the patient population. Similar to the other DLL3-targeted bi-therapies, the most common adverse events included CRS in 57%, dysgeusia in 23%, and pyrexia in 21% of the patients. CRS events were mostly mild. They occurred more frequently in the first two to three doses. 9% of the patients experienced ICANS, of which 3% were graded as Grade 3 or higher. And let's review the efficacy results. Responses were only seen in patients who received 90 microgram per kg or more once weekly or once every three weeks dosing. The objective response rate in patients who received an effective dose was 28%. If we review by tumor type, 21% of the small cell lung cancer patients, 27% of the extrapulmonary neuroendocrine carcinoma patients, and 70% of the large cell neuroendocrine carcinoma patients had objective response. Median duration of response was 8.5 months, though this data is immature due to short follow-up. Dr. Wermke, DLL3-targeted bispecific T-cell engagers are reshaping the treatment landscape of small cell lung cancer. This trial investigates Obrixtamig in other high-grade neuroendocrine tumors as well. Can you put this trial into context for us and explain why it may represent an important step forward? Dr. Martin Wermke: Yeah, thank you for providing me with the opportunity to discuss our data today. I think the data with Obrixtamig in small cell lung cancer are largely similar to what has been observed with other bispecific T-cell engagers such as tarlatamab with respect to the response rate and duration. It has, however, been to be mentioned that BI 1438001 had a bit more liberal inclusion criteria than other trials around. You already mentioned the fact that we allowed the inclusion of patients without mandatory brain imaging, which led to some patients having their brain mets been diagnosed during the treatment with obrixtamig and then adding to the progressive disease patients. That is something which was not the case with the tarlatamab trials where you really had to have a brain imaging before, and in the Phase 1 trial you were even required to treat the brain mets before you included the patient. So it is a bit different, more poorest patient population. I think the trial adds on existing data by being the first trial to also include non-SCLC neuroendocrine carcinoma of other origin, for example from the gastrointestinal tract, and also by including large cell neuroendocrine carcinoma of the lung, which is a really hard to treat pulmonary neoplasm which currently lacks any standardized treatment. So that is really a step forward which we will build on in the future. Dr. Ece Cali: And one thing I would note in this trial, only patients with tumor expressing DLL3 were enrolled. Can you tell us a little bit more about this target, DLL3 in the context of neuroendocrine tumors, and does DLL3 expression predict clinical outcomes after treatment with DLL3 BiTEs, or do we actually need other predictive biomarkers for these novel agents? Dr. Martin Wermke: Yeah, thank you. That's a pretty interesting question. First of all, DLL3 is an atypical notch ligand, which is expressed by the majority of neuroendocrine carcinomas, virtually absent on healthy adult tissues. Therefore, turning it really into a bona fide target for T-cell engaging therapies, pretty low risk for on-target off-tumor side effects. We found that in all the patients we screened, we had an expression rate of about 94% in small cell lung cancer, 80% of large cell neuroendocrine carcinoma of the lung were positive, and also about 80% of the extrapulmonary neuroendocrine carcinoma. So it's really a high prevalence. So the fact that we only included DLL3+ tumors still means we included most of the patients that presented with these diseases. I think at the moment there are no data suggesting a clear-cut association between DLL3 expression levels and outcome on DLL3 CD3 T-cell engagers. There's also not a lot published. If you want to find this out for tarlatamab, you have to look into their patent to really see the data, but it's not clear-cut and I'm sure we need other markers to complement that. And I think what probably plays a major role is intrinsic T-cell fitness. So the question how really diseased your T-cells are, how old you are, because age also correlates with the fitness of the immune system, and other patient characteristics such as tumor burden, we've seen all across the board that the higher the tumor burden, the lower the rate of prolonged response is in such trials. And I also think we need to focus on other components of the tumor microenvironment. So see how high the T-cell infiltration with obrixtamig is and how abundant suppressive elements like regulatory T-cells or myeloid-derived suppressive cells are. That is work which is currently being done. Data are emerging, but I don't think that at the moment we have any clear biomarker helping us to select who should not receive DLL3 T-cell engagers. Dr. Ece Cali: Those are great points and there is a lot we need to learn about how to use these novel agents in the future. I'd like to highlight the results in large cell neuroendocrine carcinoma of the lung. The response rate in this group was remarkably high at 70%. Though we should note the small sample size of only 14 patients in this trial. After first line chemoimmunotherapy, current approved options for this population have very modest clinical activity. Given these trial results, how do you envision the field moving forward for patients with large cell neuroendocrine carcinoma? Dr. Martin Wermke: Yeah, I think LCNEC is really an area which urgently needs further improvement of therapeutic standards. At the moment, as I said, there is no real standard. We are usually extrapolating from results we have in small cell lung cancer or non-small cell lung cancer, but I don't think we have too many prospective trials really informing this. Of course, 14 patients is a small sample size, but I think it's still fair to say that we can claim that DLL3 T-cell engagers are not doing worse in LCNEC than they do in SCLC. And that's why I think we really need to move forward clinical trials that are specifically targeting this population. Although I fear a bit that, given the rareness of this disease and the aggressiveness of its phenotype, that this is probably not the main focus of the pharmaceutical industry. So I think it's up to us academic investigators to really come up with investigator-initiated trials trying to fill the knowledge gaps we have here. Dr. Ece Cali: And one more thing that I want to talk about is the accessibility for these drugs. These novel agents are showing real promise in improving outcomes for patients with high-grade neuroendocrine tumors, an area where progress has been limited until very recently. However, as DLL3 BiTEs become more widely used, issues of logistics and access come into sharper focus. With unique toxicities and the specialized monitoring, their use is restricted to certain centers. Looking ahead, what kinds of strategies could help mitigate some of these adverse events or make these treatments more broadly available? Dr. Martin Wermke: Yeah, I think if you look at countries like the United States where tarlatamab has already been approved, we can see how the management strategies are evolving. I've heard about a colleague equipping their patients with thermometers and a pill of Dexamethasone, alongside with a temperature control protocol and clearly instructing them, "If you measure a temperature above a certain level then start taking the Dexamethasone and come back to our office and we're going to take care of you." I think that's one way to move forward. I think we are lucky in a way that CRS usually manifests within the first 24 hours. This was the same in our study, like in the tarlatamab studies. So we really know when the time of trouble is for our patients. And in this time, I think we need to instruct the patients to stay close to the hospital. I don't think we need to hospitalize all of them, but we probably need them to stay in a nearby hotel to be able to reach the emergency room if needed in a short period of time. And I think we can also learn in this strategy how to manage bispecific antibodies from the experience our colleagues in hematology had because they have been using bispecific T-cell engagers for quite some years right now and they developed strategies and networks that were able to successfully treat these patients also on an outpatient basis. And I think that is clearly an experience we need to follow, acknowledging that we are talking about diseases which are much more frequent than the standard hematology indications. Dr. Ece Cali: Thank you so much, Dr. Wermke, for this informative discussion and for sharing your perspective on this evolving field. Dr. Martin Wermke: Yeah, thank you for providing me with the opportunity to talk about data. It was really great being able to share that, and I really think that we are just at the beginning of a new exciting area for the treatment of neuroendocrine carcinomas, and I think much improvement is yet to come for our patients. Dr. Ece Cali: Yes, that's really exciting. And thank you everyone for listening to JCO Article Insights. Please come back for more interviews and article summaries and be sure to leave us a rating and review so others can find our show. For more podcasts and episodes from ASCO, please visit asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on this podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Dr. Martin Wermke's Disclosures Honoraria: Lilly, Boehringer Ingelheim, SYNLAB, Janssen, Merck Serono, GWT, Amgen, Novartis, Pfizer,  BMS GmbH & Co. KG, Regeneron, MJH/PER, Takeda Consulting or Advisory Role: Bristol-Myers Squib, Novartis, Lilly, Boehringer Ingelheim, ISA Pharmaceuticals, Amgen, immatics, Bayer, ImCheck therapeutics, AstraZeneca, Tacalyx, Regeneron, Daiichi Sankyo Europe GmbH, Zymeworks, PharmaMar, Iovance Biotherapeutics, T-Knife, Genentech Research Funding: Roche Patents, Royalties, Other Intellectual Property Travel, Accommodations, Expenses: Pfizer, Bristol-Myers Squibb, AstraZeneca,  Amgen,  GEMoaB, Sanofi/Aventis, immatics,  Merck Serono, Janssen Oncology, Iovance Biotherapeutics, Daiichi Sankyo Europe GmbH"

Dan O'Flaherty, CEO of Versamet Royalties (TSX.V: VMET), joins me to provide an update on the recent acquisition of both a silver stream and net smelter royalty on cash-flowing producing assets from Appian Capital.  We also take a deeper dive into the value proposition embedded in their portfolio of streams and royalties, and the triple-pronged approach to growth for this newer royalty company, that just listed publicly back in May of this year. Dan previously led Maverix Metals, which sold to Triple Flag in 2023, and now he's building Versamet to fill the gap between junior royalty players and the multi‑billion‑dollar majors.   Key Highlights from Our Discussion:   Closed an agreement on September 24th for the acquisition of two long-life, high-quality, producing assets from Appian Capital Advisory; with immediate cash flow for an up-front cash consideration of $125 million. Rosh Pinah Zinc - a 90% silver stream an operating underground mine in Namibia with over 55 years of mining history and a long history of resource additions and significant exploration potential Santa Rita - a 2.75% net smelter return royalty (NSR) on a top tier nickel sulphide mine located in Bahia state, Brazil, currently producing from an open pit. The Stream and NSR Royalty are expected to contribute approximately 5,000 gold equivalent ounces ("GEOs") in 2026 using analyst consensus metal prices. Cash‑flow focus: From ~10,000 GEOs in 2025 to ~20,000 GEOs by 2026, translating to over $70M in annual revenue targeted for next year, using consensus gold prices, and even higher than that at current spot prices. Balance sheet strength: Paid off initial debt out of robust revenues, before adding this recent debt on the back of these 2 acquisitions; with a roadmap to paying that back down in an accelerated fashion from quarterly cashflows. Rapid portfolio growth: Over US$400M in acquisitions since 2022, growing Versamet's market cap to over CAD$800 million. We review how several key strategic stakeholders got into partnership with Versamet including: B2Gold (33%), Sandstorm (25%), and Equinox Gold (13%) as cornerstone shareholders, providing technical strength and deal flow. Investors today can get an early mover advantage before more institutional investors and passive fund investments have entered the story. Triple-pronged approach to growth: (1) Near‑term organic growth from within their existing portfolio of royalties and streams, (2) future accretive acquisitions, and (3) the coming U.S. listing for more liquidity, a broader investor base, and the potential inclusion in funds and ETFs.     If you have any questions for Dan regarding Versamet Royalties, then please email those in to me at Shad@kereport.com.   Click here to follow the latest news from Versamet Royalties

Fred Bell, CEO of Elemental Altus Royalties (TSX.V:ELE) (OTCQX:ELEMF), and Dave Cole, CEO of EMX Royalty Corp (NYSE American: EMX) (TSXV: EMX), both join me to unpack the key transaction details, synergies, and growth profile emerging from the business combination of both companies into the emerging Elemental Royalty Corp.  In the new combined entity, Dave will be the CEO, and Fred will be the President and COO, with the balance of the management team and board being a solid blend of the 2 companies current teams.   Dave starts us off with the big-picture rationale for this merger, creating a larger royalty company of scale, graduating up to the mid-tier category, with more analyst coverage and liquidity, a better cost of capital, the financial strength from the backing of the key strategic shareholder Tether Investments, and the potential to rerate in the future to a better price to net asset value multiple more in alignment with larger royalty peers.   Fred then takes us through the transaction specifics of the merger, including the recent financing, share roll back, and US big board exchange listing that were all announced earlier this month, in concert with this business combination. Fred also outlines the importance of having Tether Investments as their key strategic shareholder, and they financially backstop the kinds of accretive acquisitions that they can now go after. He also explains why they made the choice to establish an institutional account to gain exposure to Tether Gold (XAUt), a tokenized asset backed 1:1 by physical gold, to diversify the Company's treasury and increase exposure to rising gold prices with enhanced liquidity and efficiency.   We also dive into updates on their key cornerstone royalty partner projects: Timok, Laverton, Karlawinda, and Caserones. the organic development growth still on tap in their portfolio of royalties, the future upside of the continued royalty generation strategy, and a look ahead to future larger acquisitions than were possible for both companies up until the creation of this new combined vehicle.   If you have any follow up questions for Dave or Fred regarding the merger of Elemental Altus Royalties with EMX Royalty, into the new Elemental Royalty Corp, then please email them to me at Shad@kereport.com.   In full disclosure, Shad is a shareholder of both Elemental Altus Royalties and EMX Royalty Corp at the time of this recording, and may choose to buy or sell shares at any time.   Click here to learn more about the Elemental Altus and EMX Royalty merger   Click here to view recent news on Elemental Altus Royalties   Click here to view recent news on EMX Royalty

Every masterpiece you've ever consumed likely passed through a licensing agreement first. That catchy song in your favorite commercial? Licensed. The superhero logo on your coffee mug? Licensed. The technology powering your smartphone? Licensed hundreds of times over. Licensing represents the hidden architecture behind innovation empires, allowing creators to extend their reach without surrendering control. Unlike selling your intellectual property outright, licensing lets you maintain ownership while granting permission for others to use it under specific conditions – essentially renting out a room while remaining the landlord.The potential of licensing spans virtually every form of intellectual property. Patents enable inventors to collect royalties from global manufacturers without running factories. Trademarks allow fashion brands and sports teams to appear on merchandise worldwide. Copyrights drive music, publishing, and streaming industries. Even carefully protected trade secrets can be licensed as valuable know-how.But successful licensing requires methodical preparation. You must clearly establish ownership, precisely define scope, protect confidentiality during negotiations, package assets for seamless transition, establish defensible royalty models, and determine governance structures. Finding the right licensees demands strategic targeting – from identifying companies in similar patent classes to exploring industry standards programs and attending specialized trade shows.The negotiation process benefits from structured frameworks: separating positions from interests, understanding your alternatives, presenting multiple equivalent offers, and stress-testing deals through financial modeling. Equally important is recognizing red flags: licensees who overpromise, resist transparency, fight performance standards, demand excessive exclusivity, or operate in challenging regulatory environments.Remember that licenses exist in dynamic markets with changing conditions. Know when to renegotiate (when fundamental assumptions shift), when to walk away (when partners consistently underperform), and when litigation becomes necessary (when your rights are genuinely threatened).Want to develop your own IP protection strategy? Check out "Protection for the Inventive Mind" – available now on Amazon in print and Kindle formats.Get the book!Send us a textSupport the show

In this episode, we unpack the insights from the recent IPSeries webinar exploring the evolving landscape of Collective Management Organizations (CMOs) across Africa and the globe. From the challenges of royalty collection and distribution to the legal frameworks shaping copyright enforcement, we dive into a comparative review of global versus local approaches to rights management.Experts from across the creative and legal sectors weigh in on:The role of CMOs in empowering artists and creatorsStructural and policy differences between African CMOs and their global counterpartsThe impact of digital platforms and cross-border licensingStrategies for improving transparency, accountability, and efficiencyWhether you're a creator, legal professional, or policy enthusiast, this episode offers a compelling look at how collective rights management is transforming and what it means for the future of intellectual property in Africa and beyond.So grab your headphones, settle in, and let’s explore how collective rights management is reshaping the future of intellectual property on the continent and beyond.Please leave your thoughts and opinions by commenting via email at ipseriesinfo@gmail.com or by tweeting us at @ipseries1. And don't forget to subscribe to my podcast for more intellectual property (IP) insights and analysis.Thank you for listening, and see you next time on the IP Series podcast!IPSERIES PODCAST- Facebook: https://web.facebook.com/groups/836484013662125/- Instagram: ⁠Instagram⁠- Email: ipseriesinfo@gmail.com=================================SOCIAL MEDIA BY: Rita Anwiri Chindah=================================LOGO DESIGN BY: Rita Anwiri Chindah ⁠ipseries_with_reedah | Twitter, Instagram, Facebook | https://linktr.ee/ipseries_with_reedah?subscribe

Dr. Monty Pal and Dr. Mina Sedrak discuss the science behind cancer treatment-induced accelerated aging and the development of drug therapies and technologies aimed at helping older patients and cancer survivors. TRANSCRIPT Transcript: Cancer and Aging: Researching the Path to Longer, More Vibrant Lives Dr. Monty Pal: Hello, and welcome to the ASCO Daily News Podcast. I am Dr. Monty Pal. I am a medical oncologist and professor and vice chair of medical oncology here at the City of Hope Comprehensive Cancer Center. I am also host of this podcast. Today, we are going to be talking to somebody that I consider to be my little brother, if you will, in oncology, Mina Sedrak. Mina is an expert in the area of cancer and aging, which really includes the development of drug therapies and technologies that help enable older adults and survivors to live longer, healthier, and more vibrant lives. I am really excited to chat with him. He is an expert not just in cancer and aging but also breast cancer. He was my former colleague here at City of Hope before he moved over to the UCLA Jonsson Comprehensive Cancer Center, where he is an associate professor and director there of the Cancer and Aging Program. Dr. Sedrak's research involves mechanisms behind cancer treatment-induced accelerated aging and really aims to take this science into more of a therapeutic direction, which I am super, super excited about.  Mina, thanks so much for joining us today, and just FYI for our listeners, we have all of our disclosures in the transcript of this episode. Dr. Mina Sedrak: Thank you, Monty. Thank you, Dr. Pal, for having me. I am really excited to be here. Dr. Monty Pal: I feel like we have to go on a first-name basis here with how well we know each other. So Mina, you and I together have witnessed this evolution in cancer and aging. I mean, both of us worked together here with just a legendary figure in the field of geriatric oncology, I will call it, Dr. Arti Hurria, mentor to me, mentor to you, mentor to so many. Can you give us a sense of where cancer and aging has gone since the time that you and I started here together at City of Hope? Dr. Mina Sedrak: Dr. Hurria and her collaborators, Dr. [Willliam] Dale and Dr. [Supriya] Mohile, they were like huge pioneers in the field. They were one of the very first people to highlight the importance of looking at older adults beyond just their chronological age and their comorbidities and moving us beyond just seeing patients and making decisions using what we call the eyeball test. "Oh, this person looks fit or not fit, frail or robust," to really using objective measures to assess our patient's health status and incorporate that assessment into our evaluation of the treatment, prognostication, and discussions with our patients throughout the cancer continuum. And so that is what geriatric oncology has and continues to be, and it is a huge, important part. And their work has laid the foundation to show that when we look at our patients beyond just their chronological age and we look at their functional age, and we do these objective assessments, we can gain much more deeper information to tailor the treatment for our patient that is sitting in front of us, rather than do a prescriptive treatment or over- or undertreatment in that population. So that is sort of where the field is growing, and a lot of the work now is, how do we implement that? How do we put that into clinical practice? Dr. Monty Pal: Well, let me kind of spearhead that discussion, right? I have these moments when I go to the ASCO Annual Meeting – I remember this happened to me a while ago when Dr. Jennifer Temel presented that terrific work around early palliative care interventions, right? Or it even happened to me this year, right, when Dr. Christopher Booth presented the CHALLENGE trial around exercise and colon cancer. You know, these amazing, I am going to say simple, they are not simple, but they are simple interventions relative to, you know, some of the complex drugs and mechanisms that we are using nowadays that really help outcomes for our cancer patients. The big question becomes, how do you implement, right? But my understanding is that there are easy ways for us to take tools in cancer and aging and sort of plug them into our daily practice. Am I right about that? Dr. Mina Sedrak: Yes, and that is something that they are – the Cancer and Aging Research Group, which was founded by Dr. Hurria and now is co-led by Dr. Dale, Dr. Mohile, and Dr. [Heidi] Klepin, they have been incredible at really trying to develop practical tools, like the Practical Geriatric Assessment, which is now endorsed by the ASCO and other NCCN guidelines. And so, there are tools that are becoming more and more practical to help incorporate that into clinic.  Now, what might be practical in a resource-intensive setting may not be practical in some of the limited resources, whether it is rural and/or other countries where the resources may be more limited. So that is why Cristiane Bergerot, Enrique Soto, and others have been really working hard. There was actually a really beautiful paper that was just published in the Journal of Global Oncology, where they have shown that there are guidelines [ASCO Geriatric Assessment Global Guideline] about how to implement these tests, these tools, these assessments in clinical practice, even in different resource settings. So I think we are going to get to the future where this is much more – it is definitely important, but it is much more easily ‘incorporatable' into our practice. Dr. Monty Pal: Yeah, you know how close I am to Cris, and I was so proud when I saw that paper come out. That was really exciting. You know, I skimmed it. I have to tell you, I did not get into the weeds, but it was apparent to me that, you know, some of these geriatric oncology tools are things that, you know, I could probably plug and play into my practice where I am double- and triple-booked over, you know, most slots, right? I mean, I could still probably afford a little bit of time or maybe have, like, a nurse or an extender kind of help participate in the evaluation process. I thought that was, yeah, really, really interesting. Dr. Mina Sedrak: I will just say that at UCLA, we are working with Dr. Arash Naeim, who is a geriatric oncologist, and he has developed an AI platform where the assessments can be done by an AI computer. So it is like talking to your ChatGPT. They can talk to you, and for a few minutes, they will ask you the questions. So you do not even have to fill it out on a piece of paper. You could give the patient a little iPad, put them in a private room while they are waiting for their doctor, and get the results, and it is right there for you. And so, we have been trying to think about how can technology help with the completion of the assessment, at least doing that? And I think it is actually, it has been very cool. We did a pilot study. He is writing that up, and we are going to continue to do some of this exciting work. How do we think about AI in the context of this? And, you know, older adults, they are not like what they used to be. A lot of older adults are very familiar with and comfortable with phones and computers and iPads, much more so today than they were even at the time when Dr. Hurria was alive. Dr. Monty Pal: That is so interesting. You mentioned this, the AI approach is something I have been thinking about in this context because what if, for instance, you know, we have got video monitors all over our hospital, right? What if you are actually just taking a look at that patient as they make their way towards your clinic? Capture that video, use an AI algorithm to say, "Hey, you know, the timed get-up-and-go test in this patient is not particularly good based on what I am seeing here," right? There are so many ways that you could, you know, stir the pot and come up with creative ways to get these tests done. Dr. Mina Sedrak: That's right. And Arash is looking at also sensors. So he has some studies where he is putting sensors inside people's homes, where they would put them, like, on top of an Alexa app or the equivalent. A lot of people have these apps, and basically, they can sense how you are moving around and what you are doing, just movement-wise. And then they can collect that information to gain information about your life beyond just what we are seeing in the 20-minute visit in the clinic. Even when I do a walk test where I get gait speed or physical performance, short physical performance battery, the chair sit-up, those are oftentimes a single, cross-sectional, static measure. But what about the dynamic ability of capturing what has been happening for the last 7 days? What has been happening for the last 25 days between the visits, between the cycles of chemotherapy? And could that inform how I make decisions when I see patients and who do I need to target and identify? And so, we are very excited because really at UCLA, Arash is leading the technology efforts and thinking about implementation of these important measures and these important tools but leveraging new technology. And we do not want to be behind; we want to be ahead of the game. Dr. Monty Pal: I love that idea because there is a Hawthorne effect, isn't there, where you observe a process, and it naturally gets better. I mean, when you ask that patient to get up in the clinic and move, they are probably functioning to the best of their abilities, but we could probably learn a lot from just watching how fast that patient picks up a remote control at home. Some simple movement like that that is volitional would probably help out a ton. And I got to tell you, it is so funny when you mention Arash Naeim's name. I distinctly remember him serving as an attending on the wards when he was brand new at UCLA on faculty when I was a resident there. And his dad is a legendary hematopathologist, right? Dr. Mina Sedrak: I did not know that. Dr. Monty Pal: Yeah, yeah. Faramarz Naeim wrote the book on a lot of heme-path malignancies. Incredible guy. Very, very storied hematopathologist at UCLA.  I could probably go on this topic forever, but in the interest of time, I am going to shift to something that again, I could probably talk about forever, which is this area of senescence that you are involved in. You know, you had mentioned this to me, I am going to say during your outro from City of Hope and towards your transition to UCLA, it is such an exciting area. I mean, understanding the actual biologic process of aging and using those underpinnings to really sort of tailor therapy. So tell us where the state of the science is there with this body of work that you are doing. Dr. Mina Sedrak: As I said before, we have tools now to assess patients and to then do something about the deficits. So if a patient is falling, what we do is we refer them to physical therapy where they can do fall precautions and strength training to give them the information. But all of these supportive care interventions are very important. They are great. But they oftentimes are not targeting the root cause of why they are happening. And so that is really where I have been very interested in, how can we understand why is it that something like chemotherapy or immunotherapy is causing a decline in cognitive function or a decline in physical function? And so that has really led us to think about geriatric oncology rather than a discipline of older adults, but to think about aging as a physiologic process. We are all aging. As every day goes by, we are aging. And what that means is that our bodies are accumulating damage, the cells are being exposed to various stressors, and the repair mechanisms are declining. And as we get older, it is really more damage and less repair mechanism at the cellular molecular level. And it turns out that these processes of how our cells repair and respond to damage are fundamental processes of biological aging. And there has been a large amount of preclinical and now really exciting clinical work to show that there are hallmarks that could be used to assess the rate of which we age by looking at these processes. And that includes things like epigenetics, telomeres, inflammation, and something called ‘cellular senescence.' And we have been interested in my lab in senescence because it is a unique process that has an important role in aging, but it also has a really important role in cancer. Senescence is a cell state. Cells, when they are stressed, they respond to entering this state of senescence. The stress could come from anything. It could come from an oncogene activation. It could come from a reactive oxygen species. It could come from a direct damage to the cell. But it is a cell state, just like apoptosis, necrosis. Senescence is a state in which the cell, in response to that stressor, undergoes an arrest from the G to the S phase. And that arrest is oftentimes associated with a resistance to apoptosis. So then the cell does not die, but it is alive, and it remains metabolically active. And in fact, downstream pathways of these cell cycle inhibition of this G-to-S phase lead to the increase of these transcription factors in the chromatin and lead to the development of these pro-inflammatory factors. So these cells, which can occur in various tissues in the body, can continue to live despite having developed these changes, and then they secrete these proinflammatory molecules like cytokines, chemokines, metalloproteinases, all of these, which are called the senescence-associated secretory phenotype, or SASP. And as we age, we accumulate more and more of these cells, and our bodies are no longer able – our immune system, like macrophages and T cells – are no longer able to remove them effectively. And as we accumulate them in various organs, these organs release a lot of inflammatory cytokines, and the chronic inflammation in that tissue leads to the tissue being damaged, and it does not work as well, and then it starts to decline in function. And that is believed to be how senescence plays a role in aging. It is the accumulation of senescent cells that occurs with increased damage and then the repair mechanism of clearing these cells effectively, which then leads to build up of inflammation and chronic inflammation leads up to damage in multiple tissues. Dr. Monty Pal: This concept to me is fascinating. And I guess the big question is – senescence is bad, right – is it not reasonable to think that this body of research, I mean, if you are able to sort of have a meaningful impact on senescence, it could have implications well beyond oncology. Is that fair? You really could extend lifespan all around. Is that reasonable to think, all-cause mortality? Dr. Mina Sedrak: One hundred percent. And that is what they have been shown in animal models. And the reason senescence is exciting is because it turns out that you can target these cells and you can induce apoptosis of these cells, but it requires active targeting of various pathways, but it can occur. And when it does, and it is done either genetically or pharmacologically in mice, we see that the mice can reverse damage. So if you take an old mouse and you genetically engineer it to remove senescent cells, that mouse will go from being frail to fit. And if you take a young mouse and you induce senescent cells at a high rate and you accumulate them in that mouse, that mouse, even though it is young, will become frail.  So that has really led to this exciting opportunity of, can we translate this finding that we are seeing in animals and in in vivo cells, cell cultures, into humans? And could that have a benefit beyond just one disease? Could it have a benefit in multiple diseases? And not just really longevity, which I think it would be great, but what people are really looking for is, how do we live healthy as we get older? How do we move the curve so that people are not developing chronic diseases in their 60s, but they are developing them in their 80s towards shortening the period of their life with disability rather than what we have currently, which is people are living to 70s, the average life expectancy is in the mid-70s, but they are spending 10 or 11 years in disability of that life. And so, how could we reduce that time frame? Dr. Monty Pal: This is brilliant, Mina. And for our audience, this compelling dialogue that we have had here thankfully is translating to funding for Mina's work. He just scored in the second percentile for his NIH R01 based on this topic. We are so, so proud of you. I mean, it is just remarkable work. It is not easy in the current climate to get funding, and a second percentile score is just absolutely wonderful. You know, Mina, I could probably go on with you for a couple more hours here talking about your work in cancer and aging. I think I am going to have to have you back on the podcast here. But a million thanks for sharing your thoughts here today on the ASCO Daily News Podcast.  And thanks to our listeners too. If you value the insights that you heard today on the ASCO Daily News Podcast, please do not forget to rate, review, and subscribe wherever you get your podcasts. Thanks, Mina. Dr. Mina Sedrak: Thank you so much. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Find out more about today's speakers:     Dr. Sumanta (Monty) Pal   @montypal  Dr. Mina Sedrak @minasedrakmd   Follow ASCO on social media:      @ASCO on Twitter     ASCO on Bluesky    ASCO on Facebook      ASCO on LinkedIn      Disclosures:     Dr. Monty Pal:    Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview   Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical   Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis   Dr. Mina Sedrak: Patents, Royalties, Other Intellectual Property: Up-to-Date

Elemental Altus Royalties and current CEO, Frederick Bell, sits down with MSD to chat about the announced merger with EMX Royalties. The deal is being back by new board members from Tether and will create a new mid-tier royalty company in the mining space. Fred discusses the merging of business strategies and cultures in the new company.

Top musicians are taking their music off Spotify and leaving the platform behind – but why? Kiwi musicians like Tiki Taane and The Bats have joined overseas acts like Deerhoof and King Gizzard & The Lizard Wizard in boycotting the platform, accusing it of exploitation, poor royalties, and subsidising big international acts. As it stands, each stream earns an artist around one-twentieth of a New Zealand cent. Tech commentator Paul Spain told Mike Hosking artists are making a fair point, as Spotify has been increasing their prices, but not artist payouts. LISTEN ABOVE See omnystudio.com/listener for privacy information.

Wyoming made billions from coal mining over the last 50 years, funding the government, schools, roads, parks. But President Trump's major spending bill, passed in July, gives mining companies a break on royalty fees — leaving state budgets lean. In this episode, easing coal fees comes at a price. Plus: Non-store retail spending saw double-digit year-over-year growth, small businesses suffer as they wait for tariff clarity, and stock investors basically ignore all the bad economic headlines.Every story has an economic angle. Want some in your inbox? Subscribe to our daily or weekly newsletter.Marketplace is more than a radio show. Check out our original reporting and financial literacy content at marketplace.org — and consider making an investment in our future.

Wyoming made billions from coal mining over the last 50 years, funding the government, schools, roads, parks. But President Trump's major spending bill, passed in July, gives mining companies a break on royalty fees — leaving state budgets lean. In this episode, easing coal fees comes at a price. Plus: Non-store retail spending saw double-digit year-over-year growth, small businesses suffer as they wait for tariff clarity, and stock investors basically ignore all the bad economic headlines.Every story has an economic angle. Want some in your inbox? Subscribe to our daily or weekly newsletter.Marketplace is more than a radio show. Check out our original reporting and financial literacy content at marketplace.org — and consider making an investment in our future.

It's a gritty reboot for Remember ShuffleJoin the patreon to listen to the 2nd part of this episode on Die Another Day (coming later this week) ⁠https://www.patreon.com/c/RememberShuffleGive Remember Shuffle a follow on Twitter⁠⁠⁠⁠⁠ And on Instagram⁠⁠⁠⁠ ⁠@RememberShufflePod⁠⁠⁠⁠⁠ to interact with the show between episodes. It also makes it easier to book guests. 

Your weekly guide to the music biz and how it all works. In this week's The Price of Music: an urgent-ish delve into the news that Morrissey has announced he wants to sell his ownership of The Smiths' songs… including a suggestion from Steve and Stu about how Johnny Marr might buy the songs off Morrissey via a gmail address that Morrissey put online.And then Steve and Stu take a deep dive into a fantastic question from listener Simon who asked: artists often say that they are not making enough money from music streaming but are artists REALLY worse off today in the music streaming age?To answer this, Steve and Stu wander down some... interesting pathways. They:talk to their Top Secret Sources in the artist and label world, and found out the answer… (which may surprise you);hypothesise about both Mazzy Star AND Bonnie Tyler's record contracts;chat to Spotify, which reveals to our dynamic duo about how much they paid Mazzy Star and Bonnie Tyler(!);wonder how being a ‘radio artist' pays compared to a ‘streaming artist';dig into artist deals: because the money paid from streaming doesn't go to the artist first;ask why the artists who ARE doing well from streaming platforms aren't talking about it?…and tangentially… is TPOM better to listen to on a treadmill than Hi-NRG house music? A brief discussion.And in the special post-show lock-in section just for our Patreon Superfans, Steve and Stuart prop themselves at the bar to chat about:The time Steve worked in a record shop for a day; and he immediately faced a quandary: which letter should he file PJ Harvey under?Steve gently chides Stu over his love of a Songs Of The Summer Stats List from TikTok, which includes a load of old nostalgia songsRadiohead are back – and how do you sell tickets to shows that will be massively-oversubscribed and make sure those tickets get to real fans?After Covid's impact, money spent on live music is up - and more popular than ever.  But what were Steve and Stu's first gigs after Covid?A call for your suggestions of hard-to-file records!As ever, we welcome your feedback, emails and – in particular – any questions you might have about how the music biz works!Email us: ⁠thepriceofmusicpodcast@gmail.com⁠See you next week!Steve and Stuart======Support The Price of Music on Patreon:⁠https://www.patreon.com/ThePriceofMusic⁠Follow Steve on X - @steve_lamacqFollow Stuart on X - @stuartdredgeFollow The Price of Music on X - @PriceofMusicpodFor sponsorship, email - ⁠joe@musically.com

Sting is being sued by his ex-bandmates for millions in unpaid royalties, Radiohead surprise fans by announcing their first official tour in over 7 years, the Sex Pistols are forced to cancel their upcoming North & South American tour dates due to an unexpected injury in the band, the Ronnie James Dio Stand Up and Shout for Cancer fund announces their annual Bowl for Ronnie charity event featuring Eddie Trunk and tons of musical celebrities & more!  PLUS ‘This Week in Rock & Roll History Trivia', Rock Birthdays, ‘The Best & Worst Rock Album Artwork of the Week' & so much more!Everything is up at www.rocknewsweekly.com / All socials & TikTok @rocknewsweekly Watch us LIVE, chat with us & more…Every Sunday around 2pm PST @ https://www.twitch.tv/rocknewsweeklyWatch all of our videos, interviews & subscribe at Youtube.com/@rocknewsweeklyFollow us online:Instagram.com/rocknewsweeklyFacebook.com/rocknewsweeklyTwitter.com/rocknewsweeklyTikTok.com/@rocknewsweeklyAll of our links are up at www.rocknewsweekly.com every Monday, where you canCheck it out on 8 different platforms (including Amazon Audible & Apple/Google Podcasts) #Rock #News #RockNews #RockNewsWeekly #RockNewsWeeklyPodcast #Podcast #Podcasts #Metal #HeavyMetal #Alt #Alternative #ClassicRock #70s #80s #90s #Indie #Trivia #RockTrivia #RockBirthdays #NewMusic #NewMusicReleases #Sting #ThePolice #StewartCopeland #AndySummers #SexPistols #SteveJones #RonnieJamesDio #BowlForRonnie #Radiohead #Radiohead2025Tour #Deftones #AlabamaShakes #Mudvayne #TheSmiths #MikeJoyce

In this episode I mean to talk about this summers festival season but get sidetracked by the much more interesting/boring discussion depending on your like/dislike of someone grappling with first grade math for 35 minutes as I attempt to get into what the hell live performance royalties are, does anyone ever make any and if you are a covers band....do you need permission and who gets the live mechanicals.....warning, dumb maths incomingsupport the show over at :https://patreon.com/AlanAverillPrimordial on Spotifyhttps://open.spotify.com/artist/0BZr6WHaejNA63uhZZZZek?si=yFFV8ypSSDOESUX62_0TzQsponsored by Metal Blade recordshttps://metalblade.indiemerch.com/promo code AA 2024 for 10% off your orderships worldwideFor info on my work as a booking agent go to:https://www.facebook.com/DragonProductionsOfficialor email alan@dragon-productions.comPrimordial cds/lps available fromhttps://www.metalblade.com/primordial/death metalVERMINOUS SERPENThttps://open.spotify.com/artist/54Wpl9JD0Zn4rhpBvrN2Oa?si=zOjIulHXS5y9lW1YHMhgTAdoomDREAD SOVEREIGN https://open.spotify.com/artist/60HY4pl0nbOrZA6u2QnqDN?si=sxQ5_1htR6G3WIvy1I_wXAgothAPRILMENhttps://open.spotify.com/artist/7GzLO1YJClmN5TvV4A37MJ?si=cRXSk24lQKWSqJG-B8KbWQSupport this show http://supporter.acast.com/agitators-anonymous-the-alan-averill-podcast. Hosted on Acast. See acast.com/privacy for more information.

Amazon Merch announced the roll out of three new products! I've got the royalties and the colors for the new polos, comfort colors, & quarter-zips... as well as some new colors for standard shirts!

It's here! Another Random Clippings episode! In this mini episode, I'll pull articles from my folder of stories that just don't fit anywhere else. Happy Labor Day to my USA listeners!SOURCES“Beam Up the Royalties, Shirley.” The Arizona Republic (Phoenix, Arizona), December 28, 1988. www.newspapers.com.“Citizens Fleeing Jury Seekers.” Princeton Daily Clarion (Princeton, Indiana), January 13, 1983. www.newspapers.com.“Gang of Boys Caught After Prying Open Casket in Old Cemetery Vault.” The News (Paterson, New Jersey), September 30, 1935. www.newspapers.com.“James Beard.” Wikipedia, February 22, 2025. https://en.wikipedia.org/wiki/James_Beard. “Juror Excused Because He Does Not Like Shape of Mrozek's Head.” The Seattle Star (Seattle, Washington), September 24, 1922. www.newspapers.com.“Man Fires at Snake, Shoots Off Big Toe.” San Francisco Bulletin (San Francisco, California), May 30, 1922. www.newspapers.com.“Will Wed Her Benefactor.” The Seattle Star (Seattle, Washington), September 24, 1907. www.newspapers.com.“Wins Bride After Long Court Battle.” The Inter Ocean (Chicago, Illinois), September 20, 1907. www.newspapers.com.“‘Just Returning Radio,' Says Youth In Store.” El Paso Herald-Post (El Paso, Texas), January 11, 1964. www.newspapers.com.SOUND SOURCESAl Jolson. “I'll Say She Does.” www.pixapay.com/music.InspectorJ. “Bell, Candle Damper A (H4n).wav.” November 17, 2017. www.freesound.org.Lucille Hegamin and The Dixie Daisies. “Cold Winter Blues.” www.pixabay.com/music.

On this episode of the Self-Publishing News Podcast, Dan Holloway looks at a new study on US reading habits that shows a 40 percent drop in reading for pleasure between 2003 and 2023, with possible shifts toward digital formats and functional reading. He also covers surprising findings about reading with children, the limited impact of COVID on reading trends, and the growing controversy over Audible's new royalty model. Plus, he highlights Spotify's latest audiobook experiment, a “Follow Along” feature that adds visuals to listening. Sponsors Self-Publishing News is proudly sponsored by Bookvault. Sell high-quality, print-on-demand books directly to readers worldwide and earn maximum royalties selling directly. Automate fulfillment and create stunning special editions with BookvaultBespoke. Visit Bookvault.app today for an instant quote. Self-Publishing News is also sponsored by book cover design company Miblart. They offer unlimited revisions, take no deposit to start work and you pay only when you love the final result. Get a book cover that will become your number-one marketing tool. Find more author advice, tips, and tools at our Self-publishing Author Advice Center, with a huge archive of nearly 2,000 blog posts and a handy search box to find key info on the topic you need. And, if you haven't already, we invite you to join our organization and become a self-publishing ally. About the Host Dan Holloway is a novelist, poet, and spoken word artist. He is the MC of the performance arts show The New Libertines, He competed at the National Poetry Slam final at the Royal Albert Hall. His latest collection, The Transparency of Sutures, is available on Kindle.

In this episode, we delve into Elemental Altus Royalties' impressive Q2 financial performance, spotlighting their robust cash generation strategies. David Baker, CFO of the company, walks listeners through the key highlights of the quarter and also shares on insights on year-end guidance at these elevated gold prices.

See omnystudio.com/listener for privacy information.

David Baker CFO of Elemental Altus Royalties (TSX.V:ELE) (OTCQX:ELEMF), joins me to review Q2 2025 financials, record operating cashflows, and outsized year so far of one-off payments. We also dive into a variety of royalty partner project updates, the development growth still on tap in their portfolio of royalties, and look ahead to future acquisitions.   Financial Highlights   Royalty revenue of US$9.1 million and adjusted revenue1 of US$10.5 million, up 102% on Q2 2024 Record Operating Cash Flow plus Caserones dividends of US$14.4 million, up +900% on Q2 2024 Attributable Gold Equivalent Ounces ("GEOs") of 3,184 ounces, up 73% on Q2 2024 and adjusted EBITDA of US$8.8 million, up 155% on Q2 2024 Revenue guidance increased to US$35 million to US$40 million, based on an updated US$3,000/oz gold price for 2025 US$19.7 million increase in cash in Q2 2025   Outlook   Elemental Altus remains on track to meet record guidance of 11,600 to 13,200 GEOs, translating to increased record adjusted revenue of US$35 million to US$40 million, based on a gold price of US$3,000/oz. Production is anticipated to be weighted towards the first half of the year, driven by first gold sales from the Korali-Sud royalty This guidance represents a 38% increase in GEOs and 74% year-on-year increase in adjusted revenue at the mid-point of guidance, with full exposure to higher gold prices Elemental Altus has a Normal Course Issuer Bid ("NCIB") in place to purchase up to 12,288,129 common shares in the capital of the Company   Dave and I then do a rapid-fire review of a number of royalty partner updates at Karlawinda, Caserones Korali-Sud (Diba), Bonikro, Wahgnion, Laverton, Cactus, and Mactung;  each with compelling advancement and growth opportunities.     Turning to the financial strength of Elemental Altus, Dave highlights the US$27 million in cash on hand at quarter's end, the increased revenue guidance of over US$35 million this year, upwards of US$20 million in one-off payments coming in over 2025, the $50 million credit facility on hand, and the solid strategic investor and financial backing from Tether Investments.  All of these factors position the company to review making accretive future acquisition transactions this year and moving forward.     If you have any follow up questions for Dave regarding Elemental Altus Royalties, then please email them to me at Shad@kereport.com.   In full disclosure, Shad is a shareholder of Elemental Altus Royalties at the time of this recording, and may choose to buy or sell shares at any time.   Click here to view recent news on the Elemental Altus Royalties website

Caleb Shreve, founder and CEO of Killphonic Rights, is a pioneering advocate for artist empowerment and transparency in the music industry. With a career spanning music production, publishing, and rights management, Caleb has worked with Grammy-winning talent while building a company dedicated to helping independent artists collect the royalties they're owed. His expertise bridges the gap between creative artistry and the often opaque business side of music, making him a leading voice in modernizing rights management and creating fairer revenue models for musicians worldwide.In this episode, we explore how Caleb is challenging the status quo and creating new pathways for indie artists to thrive.Key Takeaways:How “black box” royalties work—and why so much indie artist income goes unclaimed.The role NFTs and user-centric streaming models could play in reshaping music monetization.Practical steps every artist can take to protect their rights and maximize royalty collection.---→ Learn more about Caleb Shreve and Killphonic Rights at killphonicrights.com.Book an Artist Breakthrough Session with the Modern Musician team: https://apply.modernmusician.me/podcast

Original Post

Mineral and royalty owners face unique cybersecurity risks that most people never consider. From fraudulent emails requesting banking changes to sophisticated scams targeting royalty payments, cybercriminals increasingly view mineral owners as attractive targets due to their regular income streams and valuable assets. In this essential episode, we break down the most common digital threats facing mineral owners and provide straightforward, non-technical strategies to protect your personal information, financial accounts, and royalty payments. Whether you're tech-savvy or prefer to keep things simple, you'll discover practical steps you can implement immediately to safeguard your mineral income and personal data from online criminals.  As always, links to the resources mentioned in this episode can be found in the show notes at mineralrightspodcast.com.

July 15, 2025 | Are licensing fees required or gatekeeping? In this episode of The Chain, host Nimish Gera, vice president of Biologics at Mythic Therapeutics, and Ian Wilkinson, CEO of Gamma Proteins, discuss accessing antibody discovery technology through licensing fees and royalties—and whether these fees are justified or not. Wilkinson delves into the current landscape of antibody discovery technologies, including if AI-based technology warrants fees, how royalties affect both small companies and big pharma, and his background as one of the first experts in the field who offered purely free-for-service options. He also shares what excites him about antibody engineering and beyond. Links from this episode:  Mythic Therapeutics Gamma Proteins 

Django Degree is the founder and CEO of Focus on Words, a book platform that gives authors full ownership of their work, royalties, and audience. He's also the author of “I Hope You Wake Up” and “They Lied To You,” books that dive deep into truth, identity, and how we break free from the systems that shape us. His mission is clear: help authors reclaim their voice, rebuild broken systems, and eventually use the success of that work to fund a city for foster youth and orphans across the country.

Rob Liefeld returns to the CBH podcast talking about Youngblood hitting its stride, Extreme Studios becomes a hothouse of new series: Brigade, Bloodstrike, and nearly two dozen more, all while he mentors rising talents Dan Fraga, Norm Rapmund and more. Mounting costs inside Image spark sharp discussions with Jim Lee, Todd McFarlane, and Mark Silvestri, nudging Liefeld to open Maximum Press for experiments like Battlestar Galactica and Avengelyne. He talks about his exit from Image and his stint on Marvel's Heroes  Reborn, where his Captain America made headlines amidst Marvel's bankruptcy. Recharged, he launches Awesome Comics, partners with Alan Moore for an Award‑winning Supreme, and joins Golden Age legend Joe Simon to shield Fighting American in court. A family walk through Greek ruins now feeds the mythic spark in Cable, Deadpool, and their Fortnite cameos. Royalties still arrive, proof that owning your stories keeps the dream alive, which is a lesson his friend Robert Kirkman echoes with Walking Dead and Invincible. #RobLiefeld #Youngblood #ExtremeStudios #ImageComics #CreatorRights #HeroesReborn #CaptainAmerica #MaximumPress #AlanMoore #Deadpool Support the show

We welcome in Dan O'Flaherty, CEO of Versamet Royalties, for an introduction of the company and its portfolio of projects, which includes cash-royalties and streams. The company was brought to the market by the likes of Equinox Gold and Sandstorm. Dan shares insights into its strategy and the checklists it needs for adding additional assets to their portfolio.

Welcome to episode 194 of Growers Daily! We cover: when your plants are ready before the soil is, why (some) farmers should get royalties, and compost tea applications.  We are a Non-Profit!